A   B   C   D   E   F   G   H   I   J   K   L   M   N   O   P   Q   R   S   T   U   V   W   X   Y   Z


Drug Category: Respiratory Agents

Medication Class/Individual Agents: Cystic Fibrosis Transmembrane Conductance Regulator Modulators

I. Prior-Authorization Requirements

 Cystic Fibrosis Agents – Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators

Clinical Notes

Drug Details

Drug Generic Name

Drug Brand Name

PA
Status

ivacaftor Kalydeco PA  
lumacaftor / ivacaftor Orkambi PA  
tezacaftor / ivacaftor Symdeko PA  

Please note: In the case where the prior authorization (PA) status column indicates PA, both the brand and generic (if available) require PA. Typically, the generic is preferred when available unless the brand-name drug appears on the MassHealth Brand Name Preferred Over Generic Drug List. In general, when requesting the non-preferred version, whether the brand or generic, the prescriber must provide medical records documenting an inadequate response or adverse reaction to the preferred version, in addition to satisfying the criteria for the drug itself.

ivacaftor

  • A potentiator of the CFTR protein thought to work by facilitating increased chloride transport by potentiating the channel-open probability of the CFTR protein.
  • Approved for individuals ≥ six months of age with CF and one of the FDA-approved mutations in the CFTR gene that is responsive to ivacaftor.
  • Strongly recommended by the CFF for individuals with CF and specific gene mutation noted above to improve lung function and quality of life, and to reduce exacerbations.1
  • Dosing for individuals six months to < six years of age and weight 7 kg:
    25 mg packet every 12 hours- mix with 5 mL soft food or liquid and administer with fat-containing food.*
  • Dosing for individuals six months to < six years of age and weight 7 kg to < 14 kg:
    50 mg packet every 12 hours- mix with 5 mL soft food or liquid and administer with fat-containing food.*
  • Dosing for individuals six months to < six years of age and weight 14 kg or greater:
    75 mg packet every 12 hours- mix with 5 mL soft food or liquid and administer with fat-containing food.*
  • Dosing for individuals ≥ six years of age:  150 mg every 12 hours with fat-containing food.*

*Notes: Adjust dose for individuals with concomitant use of moderate and strong CYP3A inhibitors, moderate hepatic impairment, and use with caution in those with severe hepatic impairment. If possible, avoid concomitant use of CYP3A inducers (e.g., carbamazepine, rifampin, phenobarbital, phenytoin, St. John’s wort, etc).

 

lumacaftor/ivacaftor

  • A combination product that contains ivacaftor, a potentiator of the CFTR protein as well as lumacaftor, a CFTR corrector.
  • Approved for individuals ≥ two years of age with CF and two copies (homozygous) of the F508del mutation in the CFTR gene.
  • Dosing for individuals two to five years of age and weight < 14 kg:
    One packet (100mg/125 mg) every 12 hours- mix with 5 mL soft food or liquid and administer with fat-containing food.**
  • Dosing for individuals two to five years of age and weight 14 kg or greater:
    One packet (150mg/188 mg) every 12 hours- mix with 5 mL soft food or liquid and administer with fat-containing food.**
  • Dosing for individuals six to < 12 years of age:  Two tablets (100mg/125 mg) every 12 hours with fat-containing food.**
  • Dosing for individuals ≥ 12 years of age:  Two tablets (200mg/125 mg) every 12 hours with fat-containing food.**

**Notes: Adjust dose for individuals with hepatic impairment and concomitant use of strong CYP3A inhibitors (e.g., azole antifungals, clarithromycin, etc). If possible, avoid concomitant use of CYP3A inducers (e.g., carbamazepine, rifampin, phenobarbital, phenytoin, St. John’s wort, etc).

 

tezacaftor/ivacaftor

  • A combination product that contains ivacaftor, a potentiator of the CFTR protein, as well as tezacaftor, a CFTR corrector.
  • Approved for individuals ≥ six years of age with CF and two copies (homozygous) of the F508del mutation in the CFTR gene or who have at least one mutation in the CFTR gene that is responsive to tezacaftor/ivacaftor.
  • Dosing for individuals six to < 12 years of age weighing < 30 kg: One tablet (50mg/75 mg) every morning and one ivacaftor 75 mg tablet every evening with fat-containing food.***
  • Dosing for individuals six to < 12 years of age weighing ≥ 30 kg: One tablet (100mg/150 mg) every morning and one ivacaftor 150 mg tablet every evening with fat-containing food.***
  • Dosing for individuals ≥ 12 years of age:  One tablet (100mg/150 mg) every morning and one ivacaftor 150 mg tablet every evening with fat-containing food.***

***Notes: Adjust dose for individuals with moderate or severe hepatic impairment or when coadministered with moderate or strong CYP3A inhibitors (e.g., azole antifungals, clarithromycin, etc).

References

1. Mogayzel PJ, Naureckas ET, Robinson KA, Mueller G, Hadjiliadis D, Hoag JB, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2013 Apr 1;187(7):680-9.

 
Table Footnotes

II. Therapeutic Uses

FDA-approved, for example:

  • treatment of CF

Note: The above list may not include all FDA-approved indications.

Back to top


III.  Evaluation Criteria for Approval

Please note: In the case where the prior authorization (PA) status column indicates PA, both the brand and generic (if available) require PA. Typically, the generic is preferred when available unless the brand-name drug appears on the MassHealth Brand Name Preferred Over Generic Drug List. In general, when requesting the non-preferred version, whether the brand or generic, the prescriber must provide medical records documenting an inadequate response or adverse reaction to the preferred version, in addition to satisfying the criteria for the drug itself.

  • All PA requests must include clinical diagnosis, drug name, dose, and frequency.
  • A preferred drug may be designated for this therapeutic class. In general, MassHealth requires a trial of the preferred drug or clinical rationale for prescribing a non-preferred drug within a therapeutic class. Additional information about these agents, including PA requirements and preferred products, can be found within the MassHealth Drug List at www.mass.gov/druglist.
  • For recertification requests, approval may require submission of additional documentation including, but not limited to, documentation of: some or all criteria for the original approval; response to therapy; clinical rationale for continuation of use; status of member’s condition; appropriate diagnosis; appropriate age; appropriate dose, frequency, and duration of use for requested medication; complete treatment plan; current laboratory values; and member’s current weight.
  • Additional criteria may apply depending upon requested medication (see below).

 

Kalydeco

  • Documentation of all of the following is required:
    • appropriate diagnosis; and
    • member is ≥ six months of age; and
    • request is within quantity limit of 56 units/28 days; and
    • baseline body mass index (BMI) and percent predicted forced expiratory volume in one second (ppFEV1). 
  • For recertification, documentation of positive response to therapy (e.g., improvement in BMI, ppFEV1, decrease in clinical exacerbations) is required. 

 

Orkambi

  • Documentation of all of the following is required:
    • appropriate diagnosis; and
    • member is ≥ two years of age; and
    • request is within quantity limit of 112 tablets/28 days or 56 packets/28 days; and
    • baseline BMI and ppFEV1. 
  • For recertification, documentation of positive response to therapy (e.g., improvement in BMI, ppFEV1, decrease in clinical exacerbations) is required. 

 

Symdeko

  • Documentation of all of the following is required:
    • appropriate diagnosis; and
    • member is ≥ six years of age; and
    • request is within quantity limit of 56 tablets/28 days; and
    • baseline BMI and ppFEV1.
  • For recertification, documentation of positive response to therapy (e.g., improvement in BMI, ppFEV1, decrease in clinical exacerbations) is required. 


Original Effective Date: 04/2003

Last Revised Date: 11/2019


Clinical Criteria Main Page | Back to topPrevious  |  Next

Last updated 11/25/19